The purpose of the present study is to explore the interaction between LDL and their monoclonal antibodies.
maximum binding of each monoclonal antibody was unique, ranging from 20 to 95% of total 1251-labeledLDL, suggesting that LDL particles were immunochemically heterogeneous. One antibody, LP-34, had both high and low binding affinities to LDL. Another, LP-47, exhibited high affinity for isolated LDL, yet reacted poorly with native LDL in plasma, indicating that the conformation of isolated LDL differs from that of native LDL in plasma. Unlike polyclonal serum antibodies, a mixture of four monoclonal antibodies failed to precipitate LDL, but did show a drastic increase in binding to LDL. We found that only two of our monoclonal antibodies were necessary for such synergistic enhancement.
We propose that one of the monoclonal antibodies may serve as a catalytic reagent, and discuss the clinical significance of this finding.
AddItional Keyphrases: apolipoprotein . radioimmunoassay antibody binding affinity . antigen-antibody interaction A major advance in molecular immunology and biochemistry has been the production of homogeneous monoclonal antibodies (1,2). Fusion techniques (3) and potential uses of monoclonal antibodies (4, 5) have recently been reviewed.
Human plasma low-density lipoproteins (LDL) are the vehicles for the transport and uptake of cholesterol. 2 Brown and Goldstein have shown that LDL are bound by highaffinity receptorson cell membranes, internalizedvia endocytosis, and degraded in lysosomes (6, 7) . LDL are heterogeneous in sizeand chemical composition (8-13). Recently, Kane et al. (11) reported the presence of at least four major molecular forms of apolipoprotein (apo) B in circulating plasma and noted that LDL contain three of these forms: B-100, B-74, and B-26. Another study (14) also suggests that another apo B (B-48), a major component of chylomicrons, is not a precursor of apo B in LDL. Because the difference in the amino acid composition of each apo B species is slight, monoclonal antibodies will probably be necessary to distinguish such subtle changes in an antigenic determinant (4) .
The purpose of the present study is to explore the interaction between LDL and their monoclonal antibodies.
We have found that the stability of the antigenic structure of LDL differs under various temperature conditions (15). Understanding the binding properties of LDL to antibodies should allow us to map the antigenic sites, develop immunoassays for ape B, and probe the structure and metabolism of LDL. Recent studies have implicated overproduction of LDL as one of the factors causing hypercholesterolemia (16, 17), and a technique to decrease the concentrations of plasma LDL by using anti-LDL antibody affinity columns has been reported (18) . Our finding of the enhancement of the binding of LDL by the combined use of two monoclonal antibodies could provide a clinical aspect to the selection of monoclonal antibodies for affinity column preparations.
Materials and Methods

Preparative Procedures
Production of monoclonal antibodies.
The preparation, IgG subclass, and affinity of the L1C6F2 monoclonal antibody have been described previously (15, 19) . Production of three new hybridoma lines against LDL (LP-22, LP-34, and LP-47) have followed similar techniques.
In general, all hybridomas were prepared by fusing spleen cells of immunized female Balb/c mice with a nonsecreting myeloma cell line (FO) (3). To screen for antibody production, we incubated 50-100 L of the culture media from each well with 20 000 dpm of 125I-labeled LDL ('251-LDL, specific activity -2 Ci/g) and equilibrated this mixture in a radioimmunoassay buffer containing, per liter, 10 g of bovine serum albumin, 0.1 mol of sodium borate, 1 mmol of Na2EDTA, and 0.1 g of NaN3 (pH 8.5). After incubation at 4#{176}C for 16 h, we added 100 tL of staphylococcus containing protein A (IgG SORB; The Enzyme Center, Inc., Boston, MA 02111) to separate unbound '251-LDL. and by LDL-Sepharose affinitycolumn chromatography (21) . The purified LP-34 monoclonal antibody showed a single band on polyacrylamide gel electrophoresis in sodium dodecyl sulfate (22) , with a relative molecular mass of -120 000-150 000. It also showed one major band on isoelectric focusing gel electrophoresis.
The To study the binding response of monoclonal antibodies to '251-LDL prepared from normal men, we isolated LDL from fresh plasma collected from five healthy male volunteers into EDTA, 1 g/L. Lipid profiles and ages of each individual are given in Table 1 . The efficiency of radiolabeling for the LDL from the five normal subjects was 50-60% and the final specific activity was 2.2 (SD 0.25) Ci/g. No significant differences among the final specific activities of each individual's LDL were noted.
For calculations, the percent bound of total 'I-LDL is expressed by B0/T, where B0 is the total I-LDL bound to antibodies minus nonspecific binding, and T is the total 1251.. LDL used in each assay. All the assays were performed in triplicate.
Radioirnmunoassay.
We used and LP-47) did not bind 100% of the total '251-LDL, they were titered so as to bind -50% of the maximal binding. Monoclonal antibodies LP-22, LP-34, and LP-47 were diluted 640-, 80-, and 640-fold, respectively. The assay included two steps (15, 27 ): First, we added 100 L of antibodies to 100 L of 'I-LDL containing -10 ng of LDL (20000-22 000 dpm) and 100 j.iL of unlabeled LDL or diluted plasma and allowed the reaction to proceed at 4 #{176}C for 16-24 h. Second, we added 100 /.LL of IgG SORB to all tubes to separate unbound 'I-LDL as described above in the direct binding assay. To evaluate nonspecific binding, we used either normal hybridoma media or nonimmune mouse sorum; typical nonspecific binding was 2-3% of the total i251 LDL added.
For calculations, the percent bound = (B/B0) 100, where B is the totalbound 1251-LDL in the presence of unlabeled LDL standards or plasma minus nonspecific binding, and B is the total bound 125I-LDL in the absence of unlabeled LDL or plasma minus the nonspecific binding.
Lipolysis of very-low-density lipoproteins and its effect on their immunoreactivity
as determined by radioimmun.assay.
In a lipolysis experiment, performed as previously described (29), VLDL obtained from normal subjects were adjusted to (containing 50 g of bovine serum albumin per liter), we added various amounts (10-100 L) of bovine milk lipoprotein lipase (EC 3.1.1.3), 10 mg/L, and incubated the mixture, in a final volume of 300 L, at 37 #{176}C for 60 mm. VLDL samples without lipase treatment were also incubated under the same conditions. We used [14Cltriolein to monitor the degree of triglyceride hydrolysis.
To detect apo B immunoreactivity, we included VLDL containing 200 ng of apolipoproteins so that the VLDL dose would displace --50% of 'mI-LDL from monoclonal antibodies; the rest of the radioimmunoassay was as described above. Lipoprotein lipase did not interfere with the binding of '251-LDL to monoclonal antibodies nor was the standard displacement curve affected. These findings were confirmed by independent observations in the absence of VLDL as a competitor in the assays.
For calculations, the percent immunoreactivity or the percent inhibition = 100 -[(B/B0) x 1001, where B is the total bound '25I-LDL in the presence of unlabeled VLDL (in the lipase-treated or untreated sample), and B0 is the total bound '25I-LDL in the absence of VLDL. Nonspecific binding was subtracted before all calculations.
Lipid analyses. Triglyceride content of VLDL and plasma was measured by an enzymic kit method (Dow Chemical Co., Indianapolis, IN 46268) as previously described (30). Cholesterol and phospholipid contents were determined by a Beckman enzymic kit (Beckman Instruments, Inc., Carlsbad, CA 92008) procedure and a commercial enzymic kit (Nippon Shoji Kaisho, Ltd., Osaka, Japan) procedure (31), respectively.
Results
Binding Properties of 1251-LDL to Monoclonal
Antibodies
Previously we have reported that the binding of L1C6F2 monoclonal antibody to LDL is thermal dependent (15). We have now investigated three more monoclonal antibodies, obtained independently.
For all the monoclonal antibodies the binding with '251-LDL was temperature dependent, being optimal at 4#{176}C (Figure 1 ). Only monoclonal antibody LP-47 bound 'mI-LDL to the same extent at both 4#{176}C and 24#{176}C.
The degree of maximal binding (BolT) of each monoclonal antibody to '251-LDL was different ( Figure 1; Table 2 ), which suggests that LDL are immunochemically heterogeneous and that the antigemc structures present in each LDL particle are not identical. Polyclonal serum antibodies, on the other hand, bound 95% of the '251-LDL ( Figure 1 ) and this binding was not temperature dependent. Thus, the heterogeneous nature of LDL is not readily apparent unless highly specific monoclonal antibodies are used for binding experiments.
Scatchard Plot Analyses
In theory, for a given polypeptide antigen, each monoclonal antibody can recognize only one unique antigenic determinant (1). Scatchard plots (28) permit verification of the concept of single epitope-single affinity (32). As 8Data derived from a previous study (15) .
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antibody LP-34, and that the antigenic determinants (for LP-34 monoclonal antibody) are probably not uniformly exposed on LDL particles. The binding characteristics and affinities between 125I-LDL and monoclonal antibodies are given in Table 2 ; because the Scatchard plot (Figure 2 ) was not linear, we calculated the binding affinity by extrapolating from the average value of the curve. The monoclonal antibody with the highest affinity (7.5 x iO L/mol) at 4#{176}C was LP-34; as the temperature increased, the binding affinity decreased by at least 70%. The polyclonal antibodies, on the other hand, bound LDL with an affinity (4.8 x 1010 L/mol) one to two orders of magnitude greater than monoclonal antibodies and were not significantly altered by temperatures from 4#{176}C to 37#{176}C.
Binding Response of Monoclonal Antibodies to 1251..
LDL Prepared from Normal Men
The maximum binding of 125I-LDL to each monoclonal antibody being different, we decided to study whether LDL isolated from different normal individuals would yield different binding properties to each clone. We isolated LDL from five normal men, radioiodinated the samples, and used them in binding assays. The plasma and LDL lipid and protein composition for each subject are listed (Table 1) . For the labeled LDL from each normal individual the binding pattern to a given monoclonal antibody was similar at 4#{176}C (data not shown).
ImmunoreaCtivity of Apo B in VLDL after Lipolysis
After hydrolysis of VLDL triglycerides with bovine milk lipase, we determined the immunoreactivity of ape B by inhibition radioimmunoassay.
Increasing the degree of lipolysis decreased the immunoreactivity of apo B (Table 3) for all of the monoclonal antibodies tested. Lipid extracts from VLDL, LDL, or a sonicated triglyceride emulsion did not compete with 1251-LDL for binding to the monoclonal antibodies.
Enhancement of '251-LDL Binding to Monoclonal
Antibodies by Another Monoclonal Antibody
The antigenic determinant of a protein antigen is relatively small (33, 34), and monoclonal antibodies, unlike serum antibodies, recognize only a single antigenic site.
Immunoprecipitation by a monoclonal antibody is usually not possible (15). Thus, we attempted to mix our four monoclonal antibodies to create artificial "polyclonal" serum antibodies to see if they could be used as a precipitating reagent. The mixture failed to precipitate LDL, but the binding of '251-LDL to the mixed monoclonal antibodies increased greatly (Table 4) .
In theory, the mixture of 25 L of each monoclonal antibody (final vol, 100 L) should yield maximally about 800 cpm of bound '251-LDL. However, the total binding (6378 cpm) was much greater ( Table 4 ), indicating that the artificial polyclonal antibodies enhance the antigen-antibody interaction and may stabilize the antigen-antibody complexes. We also observed this enhancement when we used incubation at 4#{176}C.
To delineate which specific monoclonal antibody might play the crucial role in such enhancement, we testedcombinations of two or three selected monoclonal antibodies for their binding affinity to 'mI-LDL. Monoclonal antibodies were diluted to bind a small but detectable amount of labeled antigen (-5%). The L1CJ2 monoclonal antibody, although possessing the lowest binding affinity to LDL (5 x iC)8L/mol), bound 10-fold more LDL in the presence of LP-34 monoclonal antibody than in its absence (Table 4) . We also determined the binding affinities of the various
Fig. 2. Scatchard plot analyses of the binding between 1l-LDL and monocional antibodes at 4#{176}C
Bound LDL were determined byusing1251-LDL in the presence of increasingconcentrationsofunlabeledLDL (15 Accordingly, we devised the following strategies: (a) preincubating monoclonal antibodies at 37 #{176}C followed by reaction with LDL; and (b) preincubating 'I-LDL at 37 #{176}C followed by reaction with monoclonal antibodies (combinations of L1C6F2 and LP-34). After each preincubation, we reacted antigen with antibody at 37 #{176}C, rather than at 4 #{176}C, to avoid any reversible conformational changes of either (15) . As shown in Figure 3 
Standard Displacement Curves
Standard displacement curves for unlabeled LDL in radio- LDL and produced a curvilinear Scatchard plot (Figure 2 ), indicating that LDL contain both low-and high-affinity antigenic site(s) for the monoclonal antibodies. The possible mechanism for the high-and low-affinity site(s) may be the heterogeneity of LDL structure and chemical composition
(11-16).
The molecular orientation of ape B may vary according to its lipid and protein composition (36,37). Thus, we conclude that Scatchard analyses can also be used to study the homogeneity of the antigenic structure. however, one possibility would be that the binding of one monoclonal antibody to 1I-LDL enhanced another antibody to bind to '251-LDL, eventually allowing both antibody molecules to bind. In this case, however, the counts of bound 1I-LDL would not be increased after separation by protein A because our antibodies were not radiolabeled.
An attractive hypothesis, as illustrated in Figure 5 , is that the first monoclonal antibody serves as a catalytic-like reagent. The maximal binding of the second monoclonal antibody to LDL is "catalyzed" by the firstmonoclonal antibody. Once the first monoclonal antibody has bound to LDL and has established the binding of the second antibody to LDL, the first antibody may then dissociate from LDL (under equilibrium conditions) and 
